Company & Sponsor Intelligence

Sumitomo Pharma America, Inc.

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →
Indexed trials12
Recruiting0
Completed11
Countries3

Therapeutic footprint

adhdanxietybipolar_disorderdepressionparkinsonsschizophrenia

Indexed studies

NCT01435928PEARL Schizophrenia Maintenance
schizophrenia · United StatesPHASE3
NCT01421134Major Depressive Disorder (MDD) With Mixed Features - Flexible Dose
depression · United StatesPHASE3
NCT02734693A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting.
adhd · United StatesPHASE3
NCT01485640Lurasidone Extended Use Study
bipolar_disorder · CanadaPHASE3
NCT01423240Major Depressive Disorder With Mixed Features
depression · United StatesPHASE3
NCT00615433Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia
schizophrenia · United StatesPHASE3
NCT01566162A Twelve Week, Open Label Extension Study in Patients With Schizophrenia
schizophrenia · United StatesPHASE3
NCT03391882A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes)
parkinsons · AustriaPHASE3
NCT01575561This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296
bipolar_disorder · United StatesPHASE3
NCT06037668A Randomized, Controlled Study of Two At-Home Self-Guided Virtual Reality Interventions for Adults With Social Anxiety Disorder.
anxiety · United StatesNA
NCT00856973Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia
adhd · United StatesPHASE3
NCT01692782Adult Attention Deficit Hyperactivity Disorder
adhd · United StatesPHASE2

Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →